Please assess the completion status of the following clinical trial:

Trial Title: PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed stage IV melanoma~  * Stage M1a, M1b, or M1c~ * Mucosal, ocular, or unknown primary melanoma~* Previously untreated OR received up to 3 prior systemic therapy regimens (excluding vaccine therapy) for metastatic disease~* Plasma basic fibroblast growth factor level at least 15 pg/mL~* Measurable or evaluable disease~* Central nervous system (CNS) involvement allowed provided CNS directed therapy has been given and disease has been clinically stable for ≥ 3 months~  * Brain computed tomography (CT) scan or Magnetic resonance imaging (MRI) to confirm stable disease required ≤ 4 weeks prior to study entry~* Age: 18 and over~* ECOG Performance status of 0-2~* Life expectancy at least 6 months~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 8 g/dL (transfusions allowed)~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* Alanine Aminotransferase (ALT) no greater than 2 times ULN~* Creatinine no greater than 1.5 mg/dL OR Creatinine clearance at least 60 mL/min~* At least 4 weeks since prior interferon in the adjuvant or metastatic setting~* At least 4 weeks since prior chemotherapy in the adjuvant or metastatic setting~* At least 4 weeks since prior endocrine therapy in the adjuvant or metastatic setting~* At least 4 weeks since prior radiotherapy in the adjuvant or metastatic setting~* At least 4 weeks since prior surgery in the adjuvant or metastatic setting~* At least 4 weeks since other prior therapy in the adjuvant or metastatic setting~* Negative pregnancy test~* Fertile patients must use effective contraception~Exclusion criteria:~* Myocardial infarction within the past 6 months~* Other active malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* Other concurrent illness that would preclude study participation~* History of severe depression~* Pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEG-interferon alfa-2b (Type: EXPERIMENTAL): Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).